IUPAC/Chemical Name
N5-((S)-1-carboxy-2-(1H-indol-3-yl)ethyl)-L-glutamine
InChi Key
CATMPQFFVNKDEY-AAEUAGOBSA-N
InChi Code
InChI=1S/C16H19N3O5/c17-11(15(21)22)5-6-14(20)19-13(16(23)24)7-9-8-18-12-4-2-1-3-10(9)12/h1-4,8,11,13,18H,5-7,17H2,(H,19,20)(H,21,22)(H,23,24)/t11-,13-/m0/s1
SMILES Code
O=C(O)[C@H](CC1=CNC2=C1C=CC=C2)NC(CC[C@@H](C(O)=O)N)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
Preparing Stock Solutions
The following data is based on the
product
molecular weight
333.34
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Kolobov AA, Kolodkin NI, Zolotarev IuA, Tathill C, Navolotskaia EV. [Interaction of the synthetic immunomodulatory dipeptide bestim with murine macrophages and thymocytes]. Bioorg Khim. 2008 Jan-Feb;34(1):43-9. Russian. PubMed PMID: 18365736.
2: Zabolotnykh NV, Vinogradova TI, Vasil'eva SN. [Activating effect of bestim on the macrophages in experimental tuberculosis of varying severity]. Probl Tuberk Bolezn Legk. 2003;(10):53-6. Russian. PubMed PMID: 14669634.
3: Tkacheva AG, Kalev OF, Dolgushina AI, Antipina TV. [Impact of Bestim on the immunological status and clinical course of ulcer]. Eksp Klin Gastroenterol. 2004;(6):29-33, 163. Russian. PubMed PMID: 16259438.
4: Rudenko MY. [IMMUNE SYSTEM DATA IN PATIENTS WITH PERSISTENT RECURENT HERPES VIRUS INFECTIONS IN DYNAMICS OF COMPLEX THERAPY]. Lik Sprava. 2015 Jul-Sep;(5-6):14-20. Russian. PubMed PMID: 27089710.
5: Vinogradova TI, Vitovskaia ML, Zabolotnykh NV, Kovalenko AL, Ariél' BM, Shchegoleva RA. [The influence of immunotropic drugs on reparative processes in the lungs experimental chemotherapy drug resistant tuberculosis]. Eksp Klin Farmakol. 2014;77(7):11-5. Russian. PubMed PMID: 25322647.
6: Yakimets AV, Zozulya SA, Oleichik IV, Klyushnik TP. [Dynamics of clinical and biological indices of the asthenic symptom-complex during immunotropic therapy of patients with schizophrenia]. Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(3):70-76. doi: 10.17116/jnevro20181183170-76. Russian. PubMed PMID: 29652309.
